NanoViricides (OTCBB:NNVC) announced Wednesday it will update investors on its current development programs at the OneMedForum in New York City from June 23 - 24.
The OneMedForum connects healthcare professionals and life science-focused companies to discuss and present breakthrough technologies in the healthcare industry.
Based in West Haven, Connecticut, NanoViricides said it will use OneMedForum to discuss its current programs, including its new FluCide drug candidate which recently completed an encouraging pre-clinical animal study. NanoViricides' other drug programs, like its HIVCide, DengueCide and HerpeCide skin cream, are progressing satisfactorily, it said.
The development stage company, which specializes in developing anti-viral drugs for a host of viruses, recently announced it will begin leasing a new laboratory facility in preparation for ramped up manufacturing. NanoViricides said it is arranging to have appropriate production capabilities in place to prepare for future FDA filings.
NanoViricides uses nanomaterials to develop its nanoviricide class of drugs, which are designed to attack enveloped virus particles and dismantle them. The company is in the process of developing new drugs to work against a variety of viral diseases, including HIV, Hepatitis C, Dengue fever and the Ebola virus, among others.